Bio + Health

Investing in Function Health

Vijay Pande, Daisy Wolf, Zach Cohen, Annie Collins, and Bryan Kim Posted June 25, 2024

A few years ago, we wrote an article predicting that a consumer health company could become the biggest company in the world. More recently, we’ve argued that building new companies with magical consumer experiences that inspire behavior change is the most powerful way to extend our lifespans. The opportunity to radically reinvent healthcare to be consumer-friendly is massive—both from an economic perspective and one of maximizing our number of years on this planet.

Recently, we invested in Function Health, a company that embodies the vision and excitement we had when writing those theses. The one piece we underestimated is the current state of latent demand among consumers for a new approach to healthcare and longevity. Since launching a beta in 2023, Function has amassed nearly 50k members with little marketing.

Function aims to integrate all of your health data with all of the world’s health knowledge to best inform what actions you can take to live 100 healthy years. Function helps you fully understand what’s happening in your body, initially through the most powerful data source in healthcare: blood. Members of Function do incredibly robust lab testing of over 100 biomarkers—five times what lab work at an average annual physical includes—twice a year, and can add on a multitude of tests when they need it. Using a mixture of AI and human clinicians, Function explains the results for members in clear English.

This is just the starting point. When Function unites all of your health data—from their labs, your doctor’s EHR, and your wearable devices—into one place, the potential to improve human health is amazing. While the promise of a world-class AI doctor is more tangible than ever, the strongest LLMs and health AI companies are currently limited to providing generalized information that is directionally helpful but lacks individual context, the most vital part. Function, on the other hand, will marry individual health data with all the world’s health research to best serve individuals. Said another way, Function’s value will be compounded by the advancement of AI.

Function started a movement and has fundamentally changed consumer behavior. Prior, we’d only seen this level of organic, hockey-stick growth in companies that sell vices online. Function is the opposite: it’s a preventative, lifelong approach to health, not just a single event or doctor’s visit. It’s a new routine that enables people to catch health issues early and benefit from AI advancements. Traditional healthcare treats symptoms; Function finds root causes.

Historically, it takes 18 years for scientific medical discoveries to actually make their way into the practice of medicine. Function can change that to 18 seconds through ingesting all medical research, applying that to your health data, and serving that insight to you. Medicine is now data science, and doctors are not data scientists. Function will discover health issues before you or your doctor do. Furthermore, Function is slated to actually drive scientific discovery, facilitating virtual real-time research into cardiac health, inflammation, nutrition, and more.

We could not imagine a group better suited to build this company than the Function Health founding team. Chief Medical Officer Dr. Mark Hyman is one of the nation’s foremost experts on the subject matter having founded the Cleveland Clinic Center for Functional Medicine. CEO Jonathan Swerdlin is a repeat founder who has healed himself through Function. COO Pranitha Patil led health strategy teams at Accenture and dropped out of grad school at Harvard to found the company. CTO Mike Nemke is a Green Beret (US Army Special Forces) turned AI engineer, and CPO Seth Weisfield was a Product Design Director working on AI at Meta.

In its relatively short life as a company, Function has already facilitated over 5 million lab tests, uncovering countless critical health issues and helping members avoid unnecessary suffering. People have saved their loved ones’ lives through gifting them Function. A 51-year-old mother discovered she had stage 3 ovarian cancer. A 35-year-old fit man revealed severe risk of heart disease. A 44-year-old man caught early stage prostate cancer. All benefited from early intervention thanks to Function, and this is just the beginning. We all deserve better when it comes to our health, and Function is helping us imagine a brighter future.

Join the mission—become a member and check out the careers at Function.

About the Contributors

Daisy Wolf

is an investing partner on the Bio + Health team, focused on consumer health, the intersection of healthcare and fintech, and healthcare software.

Zach Cohen

is a partner on the consumer tech team at Andreessen Horowitz, where he focuses on companies building at the application layer in generative AI.

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
Growth

new Investing in Mind Robotics

Sarah Wang
Growth

new Investing in Nexthop AI

Raghu Raghuram, Shangda Xu, and Guido Appenzeller
Fintech

Investing in Lio

Seema Amble, James da Costa, Eric Zhou, and Brian Roberts
Bio + Health

Investing in Ease

Daisy Wolf, Anish Acharya, and Eva Steinman
Infra

Investing in QuiverAI

Yoko Li, Guido Appenzeller, and Martin Casado

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.